Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

STAT2 Antikörper (C-Term)

STAT2 Reaktivität: Human WB, ELISA Wirt: Maus Monoclonal 19G8-H2-H6 unconjugated
Produktnummer ABIN964700
  • Target Alle STAT2 Antikörper anzeigen
    STAT2 (Signal Transducer and Activator of Transcription 2, 113kDa (STAT2))
    Bindungsspezifität
    • 20
    • 16
    • 9
    • 9
    • 8
    • 7
    • 7
    • 6
    • 5
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    C-Term
    Reaktivität
    • 111
    • 44
    • 38
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Human
    Wirt
    • 113
    • 9
    • 1
    Maus
    Klonalität
    • 103
    • 20
    Monoklonal
    Konjugat
    • 63
    • 9
    • 8
    • 7
    • 4
    • 4
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    Dieser STAT2 Antikörper ist unkonjugiert
    Applikation
    • 101
    • 55
    • 42
    • 28
    • 27
    • 21
    • 13
    • 7
    • 7
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), ELISA
    Spezifität
    This Protein-A purified antibody is directed against human STAT2 protein. A BLAST analysis was used to suggest cross-reactivity with STAT2 protein from human, rat (73%) and mouse (76%), sources based on homology with the immunizing sequence. Reactivity against homologues from other sources is not known.
    Produktmerkmale
    STAT2 is a member of the STAT family of transcription factors. Unlike other STATs, STAT2 is unique as it can only be activated by interferons (IFNs). STAT2 is a critical component in mediating many IFN-stimulated biological activities including antiproliferation and antiviral responses. Upon IFN treatment, STAT1 and STAT2 become tyrosine phosphorylated, assemble as heterodimers that bind IRF9 to form the ISGF3 complex. This complex translocates to the nucleus, binds to promoters of IFN-stimulated genes and mediates gene transcription. Consequently, mutations in STAT2 or loss of STAT2 expression leads to impairment in IFN signal transduction and gene activation. IFN-alpha is an approved drug for the treatment of several forms of cancer. Yet only a subset of patients who receive IFN-alpha therapy benefit from the treatment. Given that STAT2 is activated by IFNs, it is important to define if the reduced or lack of antitumor effects seen in cancer patients on IFN therapy is due to in defects in STAT2 function. Our goal is to identify regions/motifs within the structural domains of STAT2 that not only are essential for the tyrosine phosphorylation of STAT2, but also regulate the antitumor effects of IFN-alpha. Collectively, the results of our studies will emphasize the physiological role of STAT2 in cancer. From a clinical viewpoint, cancer patients who may benefit the most from receiving IFN-alpha therapy can be selected based on their STAT2 function.
    Sterilität
    Sterile filtered
    Immunogen
    This monoclonal antibody was produced by repeated immunizations with a synthetic peptide corresponding to residues near the carboxy terminus of mouse STAT2 protein.
    Immunogen Type: Peptide
    Klon
    19G8-H2-H6
    Isotyp
    IgG2a kappa
    Top Product
    Discover our top product STAT2 Primärantikörper
  • Applikationshinweise
    This Protein-A purified antibody has been tested for use in ELISA and western blotting.  Specific conditions for reactivity should be optimized by the end user.  Expect a band approximately 113 kDa in size corresponding to STAT2 protein by western blotting in the appropriate cell lysate or extract.
    Kommentare

    Gene Name: STAT2

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1.0 mg/mL
    Buffer
    0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C/-20 °C
    Informationen zur Lagerung
    Store vial at 4 °C prior to restoration. For extended storage aliquot contents and freeze at -20 °C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4 °C as an undiluted liquid. Dilute only prior to immediate use. Expiration date is one (1) year from date of opening.
    Haltbarkeit
    12 months
  • Target
    STAT2 (Signal Transducer and Activator of Transcription 2, 113kDa (STAT2))
    Andere Bezeichnung
    STAT2 (STAT2 Produkte)
    Synonyme
    wu:fj84d07 antikoerper, p113 antikoerper, stat2 antikoerper, 1600010G07Rik antikoerper, AW496480 antikoerper, ISGF-3 antikoerper, P113 antikoerper, STAT113 antikoerper, signal transducer and activator of transcription 2 antikoerper, AGAP000099-PA antikoerper, stat2 antikoerper, STAT2 antikoerper, Stat2 antikoerper
    Hintergrund
    STAT2 is a member of the STAT family of transcription factors.  Unlike other STATs, STAT2 is unique as it can only be activated by interferons (IFNs). STAT2 is a critical component in mediating many IFN-stimulated biological activities including antiproliferation and antiviral responses. Upon IFN treatment, STAT1 and STAT2 become tyrosine phosphorylated, assemble as heterodimers that bind IRF9 to form the ISGF3 complex.  This complex translocates to the nucleus, binds to promoters of IFN-stimulated genes and mediates gene transcription.  Consequently, mutations in STAT2 or loss of STAT2 expression leads to impairment in IFN signal transduction and gene activation.  IFN-alpha is an approved drug for the treatment of several forms of cancer. Yet only a subset of patients who receive IFN-alpha therapy benefit from the treatment.  Given that STAT2 is activated by IFNs, it is important to define if the reduced or lack of antitumor effects seen in cancer patients on IFN therapy is due to in defects in STAT2 function. Our goal is to identify regions/motifs within the structural domains of STAT2 that not only are essential for the tyrosine phosphorylation of STAT2, but also regulate the antitumor effects of IFN-alpha.  Collectively, the results of our studies will emphasize the physiological role of STAT2 in cancer.  From a clinical viewpoint, cancer patients who may benefit the most from receiving IFN-alpha therapy can be selected based on their STAT2 function.
    Synonyms: Stat2, Signal transducer and activator of transcription 2, p113
    Gen-ID
    6773, 4885615
    UniProt
    P52630
    Pathways
    JAK-STAT Signalweg, Hepatitis C, CXCR4-mediated Signaling Events
Sie sind hier:
Kundenservice